Phaseline

Companies › OrthoTrophix

OrthoTrophix: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TPX-100–Phase 2Osteoarthritis (OA) of the KneeMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06865079TPX-100Phase 2Osteoarthritis (OA) of the KneeImmunologyMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines Resolve Therapeutics Elevara Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.